Please be aware these summaries are produced voluntarily by Biomedical Science students and are their interpretations of the information and findings. This information is reviewed by our Research Analyst Kristina Backlund MMSc. The National Lottery Community Fund and Ionis Pharmaceuticals, Inc have contributed to the funding of the Research Analyst role.
Alex TLC assumes no responsibility or liability for any errors or omissions in the content of these summaries. The information contained in the research summaries is provided on an “as is” basis with no guarantees of completeness, accuracy, usefulness, or timeliness. If you are unsure of any of the details within the summaries, please refer to the actual articles or contact info@alextlc.org
We have developed a database of research summaries that include leukodystrophy articles, clinical trials and pharmaceutical press releases to allow our community to easily read about relevant recent research developments.
Please use the drop down boxes below to narrow your search. You can search for condition specific summaries or to view our monthly research summaries which are sent out via email to our community, please select ‘Monthly summary’.
GM2 Gangliosidosis https://www.cureus.com/articles/530138 Sandhoff disease is a rare genetic disorder caused by changes in the HEXB gene that prevents certain fatty substances from being broken down properly. Their buildup in nerve cells can gradually affect movement, coordination, and sometimes mental health. Symptoms in later-onset forms can appear like other neurological or psychiatric conditions, which makes […]
GM2 gangliosidosis and Krabbe disease https://investors.polaryx.com/pr/polaryx-therapeutics-advances-operational-readiness-for-soteria-phase-2-basket-trial Polaryx Therapeutics is finishing getting ready for the start of the SOTERIA Phase 2 basket trial which they aim to initiate in the fourth quarter of 2026. SOTERIA is a Phase 2, open-label, single arm trial where all participants receive the same drug. It is designed to evaluate the […]
GM2 gangliosidosis https://www.azafaros.com/news-media/azafaros-completes-enrollment-of-phase-3-navigate-study-evaluating-nizubaglustat-for-the-treatment-of-patients-with-gm1-gm2-gangliosidoses Azafaros’s Phase 3 NAVIGATE study for treatment of patients with GM1/GM2 Gangliosidosis and Niemann-Pick type C diseasehas completed enrolment of patients with GM1/GM2 Gangliosidosis. The Phase 3 GM1/GM2 study enrolled a minimum of 75 patients across 25 clinical sites in 13 countries. The study is evaluating oral administration of nizubaglustat compared to […]
GM2 gangliosidosis https://www.sciencedirect.com/science/article/pii/S1096719226004476 GM2 gangliosidoses and Niemann–Pick type C (NPC) disease are rare inherited conditions that damage the brain and nervous system over time. People living with these disorders can experience difficulties with movement, balance, speech, swallowing, learning, and seizures. While treatments are available to help slow NPC disease, there are currently no disease-modifying therapies […]
GM2 gangliosidosis https://www.sciencedirect.com/science/article/pii/S2666379126001795 GM2 gangliosidosis, which includes Tay‑Sachs and Sandhoff disease, is a severe inherited condition where the brain cannot break down a fatty substance called GM2 ganglioside. As GM2 builds up, it damages nerve cells and leads to progressive neurological decline. There are currently no approved treatments that can stop or reverse the disease. […]
Krabbe Disease and GM2 Gangliosidosis https://investors.polaryx.com/pr/polaryx-therapeutics-receives-us-fda-fast-track-designations-for-all-four-indications-to-be-evaluated-in-the-soteria-basket-trial Polaryx Therapeutics has been granted Fast Track Designation (FTD) for PLX-200 for the treatment of Krabbe disease, GM2 Gangliosidosis and Juvenile Neuronal Ceroid Lipofuscinosis (JNCL/CLN3 disease). This treatment is being studied in their SOTERIA Phase 2 basket trial. The Fast Track program is a regulatory program that expedites the development and review of drugs intended to treat serious conditions and address unmet medical needs. This will help speed up and make […]
GM1 and GM2 gangliosidoses https://www.azafaros.com/news/azafaros-announces-key-scientific-oral-and-poster-presentations-on-nizubaglustat-accepted-for-worldsymposium-2026/l261c14?_gl=1*c081jt*_up*MQ..*_ga*MTAxODA4NjIwNy4xNzcxNDQwOTQ0*_ga_TSKRP1W66D*czE3NzE0NDA5NDMkbzEkZzAkdDE3NzE0NDA5NDMkajYwJGwwJGgyMDM0NDM4Njgx
GM2 Gangliosidosis also known as Tay-Sachs disease https://www.jci.org/articles/view/183434 GM2 Gangliosidosis also known as Tay-Sachs disease is a rare hereditary brain disorder caused by a defect in the HEXA gene, which prevents cells from breaking down a fatty substance called GM2 ganglioside. This buildup damages nerve cells and leads to progressive loss of movement and mental […]
